| Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology. | |
| | |
MedLine Citation:
|
PMID: 21936704 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Abstract Cyclosporine A (CsA), a powerful immunosuppressant drug effective in treating a variety of dermatologic diseases, is often avoided due to potential adverse side effects such as skin cancer. CsA-induced skin cancers are well documented in organ transplant literature. This association is less clear when dermatologic guidelines are followed (e.g., low dose, healthy patients, time-limited use, no other immunosuppressive agents, etc.). Marcil and Stern estimated increased risk of squamous cell carcinoma (SCC) after CsA treatment equivalent to 200 PUVA treatments while the original data collected by Sandoz Ltd. reported a significantly less skin malignancies at doses of 5 mg/kg/day or less. Reviewing 60 studies and over 1700 patients in 25 years of existing US and international multicenter studies revealed 63 patients (less than 1%) with skin cancer. No skin cancers were reported with 6 months continuous use or up to 2 years of intermittent therapy. PUVA phototherapy overwhelmingly preceded CsA use in reported cases. Overall, 14 case reports were found suggesting CsA-induced skin cancers with the majority either having violated accepted dermatologic safety guidelines or enrolling patients with significant pre-existing carcinogenic risk factors. When reviewing over 25 years of dermatologic experience worldwide, it is not clearly substantiated that skin cancer risk is necessarily increased in patients using CsA. |
| | |
Authors:
|
Matthew W Muellenhoff; John Y Koo |
Related Documents
:
|
17311804 - Comparison of genotoxic potency of styrene 7,8-oxide with gamma radiation and human can... 2302714 - Differential cytotoxicity of diaziquone toward chinese hamster ovary cells under hypoxi... 1853354 - Dangerous and cancer-causing properties of products and chemicals in the oil refining a... 3940784 - Asbestos burden and the pathology of lung cancer. 21338234 - Awareness and assessment of risk factors for lung cancer in residents of pokhara valley... 11190414 - Patient-clinician choice in palliation of metastatic prostate cancer. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-9-21 |
Journal Detail:
|
Title: The Journal of dermatological treatment Volume: - ISSN: 1471-1753 ISO Abbreviation: - Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-9-22 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8918133 Medline TA: J Dermatolog Treat Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
SIERRADERM, Center for Dermatology, Grass Valley, California , USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical Characteristics of Acoustic Trauma Caused by Gunshot Noise in Mass Rifle Drills without Ear...
Next Document: Maintenance of human embryonic stem cells in mesenchymal stem cell-conditioned media augments hemato...